We are live on
!
Find out more
EC
EcoR1 Capital Portfolio holdings
AUM
$2.06B
1-Year Est. Return
215.32%
This Fund
S&P 500
This Quarter
Est. Return
+20.21%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.06B
AUM Growth
-$300M
(-13%)
Cap. Flow
-$581M
Cap. Flow
% of AUM
-28.26%
Top 10 Holdings %
Top 10 Hldgs %
86.31%
Holding
41
New
11
Increased
3
Reduced
4
Closed
8
Avg Time Held Equity + Options
4.9
quarters
Top 10 Avg Time Held Equity + Options
4.3
quarters
Top 20 Avg Time Held Equity + Options
4.1
quarters
Avg Time Held Equity only
5.3
quarters
Top 10 Avg Time Held Equity only
4.3
quarters
Top 20 Avg Time Held Equity only
4.1
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
First Tracks Biotherapeutics
TRAX
|
+$59.3M |
| 2 |
Fulcrum Therapeutics
FULC
|
+$39.8M |
| 3 |
CG Oncology
CGON
|
+$25.6M |
| 4 |
Legend Biotech
LEGN
|
+$21.6M |
| 5 |
Stoke Therapeutics
STOK
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Jazz Pharmaceuticals
JAZZ
|
+$323M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$238M |
| 3 |
Crinetics Pharmaceuticals
CRNX
|
+$156M |
| 4 |
Xencor
XNCR
|
+$26.3M |
| 5 |
Relay Therapeutics
RLAY
|
+$17.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.95% |
| 2 | Miscellaneous | 1.95% |
| 3 | Financials | 0.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Zymeworks
ZYME
$1.8B
| $600M | 29.19% |
22,970,388
| – | – |
2022 Q4
14 quarters
|
|
2
AnaptysBio
ANAB
$1.36B
| $532M | 25.86% |
7,880,094
| – | – |
2019 Q4
26 quarters
|
|
3
Aktis Oncology
AKTS
$926M
| $155M | 7.56% |
4,824,469
| – | – |
2026 Q1
1 quarter
|
|
|
4
CG Oncology
CGON
$5.53B
| $106M | 5.16% |
1,494,300
+392,300
| +36% | +$25.6M |
2025 Q4
2 quarters
|
|
5
Eton Pharmaceutcials
ETON
$1.52B
| $78.6M | 3.82% |
2,171,938
| – | – |
2024 Q3
7 quarters
|
|
6
CRISPR Therapeutics
CRSP
$4.84B
| $75.8M | 3.68% |
1,389,276
| – | – |
2024 Q1
9 quarters
|
|
7
Oric Pharmaceuticals
ORIC
$1.17B
| $72.9M | 3.54% |
6,728,116
| – | – |
2020 Q2
24 quarters
|
|
|
8
First Tracks Biotherapeutics
TRAX
$1.13B
| $63.9M | 3.11% |
+3,174,519
| New | +$59.3M |
2026 Q2
0 quarters
|
|
9
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.9B
| $50M | 2.43% |
1,667,119
| – | – |
2021 Q3
19 quarters
|
|
10
Neurogene
NGNE
$431M
| $40M | 1.94% |
1,271,342
| – | – |
2023 Q4
10 quarters
|
|
|
11
CALL
CG Oncology
CGON
$5.53B
| $39.9M | 1.94% |
+561,500
| New | +$36.7M |
2026 Q2
0 quarters
|
|
|
12
Stoke Therapeutics
STOK
$1.45B
| $24M | 1.17% |
735,000
+635,000
| +635% | +$20.4M |
2026 Q1
1 quarter
|
|
|
13
Fulcrum Therapeutics
FULC
$281M
| $24M | 1.17% |
+6,549,866
| New | +$39.8M |
2026 Q2
0 quarters
|
|
|
14
Legend Biotech
LEGN
$3.48B
| $23.1M | 1.12% |
+800,000
| New | +$21.6M |
2026 Q2
0 quarters
|
|
15
BridgeBio Oncology
BBOT
$237M
| $21.5M | 1.05% |
2,823,126
| – | – |
2025 Q3
3 quarters
|
|
16
MBX Biosciences
MBX
$2.36B
| $21.4M | 1.04% |
388,500
-388,500
| -50% | -$13.6M |
2024 Q3
7 quarters
|
|
17
Zenas BioPharma
ZBIO
$1.64B
| $20M | 0.97% |
789,500
| – | – |
2025 Q4
2 quarters
|
|
18
Atara Biotherapeutics
ATRA
$93.4M
| $17.8M | 0.87% |
1,552,000
+1,452,407
| +1,458% | +$11.6M |
2023 Q4
10 quarters
|
|
|
19
Relay Therapeutics
RLAY
$3.8B
| $13.1M | 0.63% |
697,948
-1,206,814
| -63% | -$17.5M |
2026 Q1
1 quarter
|
|
20
Aura Biosciences
AURA
$650M
| $11.8M | 0.58% |
+1,666,667
| New | +$11.9M |
2026 Q2
0 quarters
|
|
21
Odyssey Therapeutics
ODTX
$829M
| $10.4M | 0.51% |
+555,555
| New | +$9.74M |
2026 Q2
0 quarters
|
|
22
Eikon Therapeutics
EIKN
$364M
| $9.56M | 0.46% |
732,606
| – | – |
2026 Q1
1 quarter
|
|
23
Pharvaris
PHVS
$2.11B
| $8.13M | 0.4% |
+235,000
| New | +$7.11M |
2026 Q2
0 quarters
|
|
24
Zura Bio
ZURA
$405M
| $6.96M | 0.34% |
1,179,715
| – | – |
2026 Q1
1 quarter
|
|
25
Phathom Pharmaceuticals
PHAT
$566M
| $6.78M | 0.33% |
625,000
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
RHJA
ST
ABTD
CFA
DWT
RMC
SIC
FWTB
EcoR1 Capital's Q2 2026 Portfolio in Review
As of Q2 2026, EcoR1 Capital held 41 positions worth $2.06B, down 13% from $2.36B the previous quarter. Its ten largest holdings account for 86% of the portfolio.
EcoR1 Capital withdrew a net $581M in Q2 2026, closing 8 positions and reducing 4 holdings. Its most notable exit was Jazz Pharmaceuticals, an estimated $323M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, EcoR1 Capital opened a new position in First Tracks Biotherapeutics worth $63.9M.
- EcoR1 Capital's largest Q2 2026 buy was First Tracks Biotherapeutics: 3,174,519 shares worth $63.9M.
- EcoR1 Capital added most to CG Oncology in Q2 2026, an estimated $25.6M increase.
- EcoR1 Capital's biggest Q2 2026 reduction was Relay Therapeutics, cutting an estimated $17.5M.
- EcoR1 Capital fully exited Jazz Pharmaceuticals in Q2 2026, selling an estimated $323M.
- EcoR1 Capital's ten largest holdings make up 86% of its $2.06B portfolio in Q2 2026.
- EcoR1 Capital opened 11 new positions and closed 8 in Q2 2026.
- EcoR1 Capital's portfolio value fell 13% quarter-over-quarter to $2.06B.
Based on EcoR1 Capital's 13F filing for Q2 2026, filed 14 Aug 2026.